R J Samulski
Overview
Explore the profile of R J Samulski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
7808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thampi P, Seabaugh K, Pezzanite L, Chu C, Phillips J, Grieger J, et al.
Gene Ther
. 2023 Sep;
30(12):792-800.
PMID: 37696981
Gene therapy approaches using adeno-associated viral vectors have been successfully tested in the equine post-traumatic osteoarthritis (PTOA) model. Owing to differences in the levels of transgene expression and adverse tissue...
2.
Wang M, Sun J, Crosby A, Woodard K, Hirsch M, Samulski R, et al.
Gene Ther
. 2016 Nov;
24(1):49-59.
PMID: 27834949
Recent hemophilia B clinical trials using adeno-associated virus (AAV) gene delivery have demonstrated much lower coagulation factor IX (FIX) production in patients compared with the high levels observed in animal...
3.
Powell S, Khan N, Parker C, Samulski R, Matsushima G, Gray S, et al.
Gene Ther
. 2016 Sep;
23(11):807-814.
PMID: 27628693
No adeno-associated virus (AAV) capsid has been described in the literature to exhibit a primary oligodendrocyte tropism when a constitutive promoter drives gene expression, which is a significant barrier for...
4.
Hemphill D, McIlwraith C, Slayden R, Samulski R, Goodrich L
Osteoarthritis Cartilage
. 2015 Dec;
24(5):902-11.
PMID: 26706703
Objective: IGF-I is one of several anabolic factors being investigated for the treatment of osteoarthritis (OA). Due to the short biological half-life, extended administration is required for more robust cartilage...
5.
Hirsch M, Wolf S, Samulski R
Methods Mol Biol
. 2015 Nov;
1382:21-39.
PMID: 26611576
Gene delivery using recombinant adeno-associated virus (rAAV) has emerged to the forefront demonstrating safe and effective phenotypic correction of diverse diseases including hemophilia B and Leber's congenital amaurosis. In addition...
6.
Wang M, Crosby A, Hastie E, Samulski J, McPhee S, Joshua G, et al.
Gene Ther
. 2015 Jul;
22(12):984-92.
PMID: 26125606
Patients with neutralizing antibodies (Nabs) against adeno-associated virus (AAV) are usually excluded from the treatment with AAV vectors. To develop a standard assay for detecting Nab inhibition activity, we systematically...
7.
Goodrich L, Grieger J, Phillips J, Khan N, Gray S, McIlwraith C, et al.
Gene Ther
. 2015 Apr;
22(7):536-45.
PMID: 25902762
A gene therapeutic approach to treat osteoarthritis (OA) appears to be on the horizon for millions of people who suffer from this disease. Previously we described optimization of a scAAVIL-1ra...
8.
Bartlett J, Samulski R
Methods Mol Med
. 2014 Feb;
7:25-40.
PMID: 24493416
The development of gene transfer vectors from the human parvovirus, adeno-associated virus (AAV), has provided scientists with an efficient and effective way of delivering genes into mammalian cells. This chapter...
9.
Lompre A, Hadri L, Merlet E, Keuylian Z, Mougenot N, Karakikes I, et al.
Gene Ther
. 2013 Mar;
20(9):901-12.
PMID: 23535897
Coronary artery disease represents the leading cause of mortality in the developed world. Percutaneous coronary intervention involving stent placement remains disadvantaged by restenosis or thrombosis. Vascular gene therapy-based methods may...
10.
Ferreira J, Hirsch M, Zhang L, Park Y, Samulski R, Hu W, et al.
Gene Ther
. 2012 Mar;
20(2):158-68.
PMID: 22402320
Multipotent adult progenitor cells (MAPCs) are bone marrow-derived stem cells with a high growth rate suitable for therapeutical applications as three-dimensional (3D) aggregates. Combined applications of osteogenically differentiated MAPC (OD-MAPC)...